ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, : ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Non-Viral Transfection Reagents and Systems Market, By Type, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1515507
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 299 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,535,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,488,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,884,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®Æ÷Æ® ÇÏÀ̶óÀÌÆ®

ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 7¾ï 8,623¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â CAGR 8.2%·Î È®´ë

ºñ¹ÙÀÌ·¯½º¼º °¨¿° ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå ¿ªÇÐ

ÀÓ»ó ÇöÀå¿¡¼­ÀÇ ºñ¹ÙÀÌ·¯½º¼º °¨¿° ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ºñ¹ÙÀÌ·¯½º¼º ¼¼Æ÷ÁÖ ÁÖÀÔÀº ±âÁ¸ ¹æ¹ý¿¡ ´ëÇÑ À¯·ÂÇÑ ´ë¾ÈÀ¸·Î, ¶Ñ·ÇÇÑ ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀåÁ¡¿¡´Â ºü¸¥ ½Ã°£, »ý¹°ÇÐÀû È¿À²¼º Çâ»ó, ¼¼Æ÷ µ¶¼º °¨¼Ò, ´õ ´Ù¾çÇÑ ÇÙ»ê Àü´Þ ´É·Â µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÓ»ó ÀÀ¿ë¿¡¼­ ºñ¹ÙÀÌ·¯½º¼º Àü»ç ½Ã¾àÀÇ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀº ±× ¼ºÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã¾àÀº siRNA, miRNA, Ä¡·á¿ë ´Ü¹éÁúÀ» ¾ÏȣȭÇÏ´Â DNA ÇÃ¶ó½º¹Ìµå ¹× CRISPR/Cas9 À¯Àüü ÆíÁý Åø¿Í °°Àº Ä¡·á¿ë ÇÙ»ê Àü´ÞÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ´É·ÂÀº À¯ÀüÁúȯ, ¾Ï, °¨¿°¼º Áúȯ µî ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ À¯ÀüÀÚ Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖ´Â ±æÀ» ¿­¾îÁÙ °ÍÀÔ´Ï´Ù.

ÇöÀç »óȲÀº ÷´Ü ºñ¹ÙÀÌ·¯½º¼º ¼¼Æ÷Ä¡·á ½Ã¾à ¹× ½Ã½ºÅÛ °³¹ß¿¡ Àû±ØÀûÀÎ ¿©·¯ ±â¾÷ÀÇ È°µ¿ÀÌ ±ÞÁõÇϰí ÀÖÀ½À» ¹Ý¿µÇÕ´Ï´Ù. ¿¹¸¦ µé¾î ÃÖ±Ù ¼¼Æ÷Ä¡·á Àü¹®°¡ÀÎ ¹ÙÀÌ¿À¼¾Æ®¸®Å©(BioCentriq)¿Í MITÀÇ ½Å»ý±â¾÷ÀÎ Ä«ÀÌÅ䯿(Kytopen)Àº Çõ½ÅÀûÀÎ ¼¼Æ÷Ä¡·áÁ¦ Á¦Á¶ ±â¼úÀ» °³¹ßÇϱâ À§ÇØ Çù·ÂÇϰí ÀÖ½À´Ï´Ù.

ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ¸Å³â ¾à 8.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯Çüº° ¼¼ºÐÈ­¿¡¼­´Â ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾àÀÌ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿ëµµº°·Î´Â ¿¬±¸¿ëÀÌ 2023³â ÁÖ¿ä À¯ÇüÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î´Â Á¦¾àȸ»ç°¡ 2023³â ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ 2023³â ¸ÅÃâ¿¡¼­ ¼±µÎ¸¦ Â÷ÁöÇß½À´Ï´Ù.

ºñ¹ÙÀÌ·¯½º¼º Àü»ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°è ºñ ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀåÀº À¯Çü, ¾ÖÇø®ÄÉÀ̼Ç, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº À¯Çü¿¡ µû¶ó ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù : ºñ ¹ÙÀÌ·¯½º¼º ÁÖÀÔ ½Ã¾à, Àü±â Æ÷¶ô¼± ±â¹Ý ÁÖÀÔ ½Ã½ºÅÛ, ±âŸ ºñ ¹ÙÀÌ·¯½º¼º ÁÖÀÔ ½Ã½ºÅÛ. ÀÏ·ºÆ®·ÎÆ÷·¹À̼ÇÀº ÇÙ»êÀÇ Á¸ÀçÇÏ¿¡ ¼¼Æ÷¿¡ Àü±â ÆÞ½º¸¦ °¡ÇÏ¿© ¼¼Æ÷¸·¿¡ ÀϽÃÀûÀÎ ±â°øÀ» Çü¼ºÇÏ¿© À¯Àü ¹°ÁúÀÌ Ä§ÅõÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÏ·ºÆ®·ÎÆ÷·¹À̼ÇÀº ³ôÀº ÁÖÀÔ È¿À²·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, ƯÈ÷ ÁÖÀÔÀÌ ¾î·Á¿î ¼¼Æ÷³ª Ãʱ⠼¼Æ÷¿¡ È¿°úÀûÀÔ´Ï´Ù. ÀÏ·ºÆ®·ÎÆ÷·¹À̼ÇÀº ÀϽÃÀûÀÎ ÁÖÀÔÀ̳ª ¾ÈÁ¤ÀûÀÎ ÁÖÀÔ¿¡ »ç¿ëÇÒ ¼ö ÀÖÁö¸¸, Ư¼öÇÑ Àåºñ¿Í ´Ù¾çÇÑ ¼¼Æ÷Á¾¿¡ ´ëÇÑ ÃÖÀûÈ­°¡ ÇÊ¿äÇÕ´Ï´Ù.

½ÃÀåÀº ¿ëµµ¿¡ µû¶ó ÀÓ»ó°ú ¿¬±¸¶ó´Â µÎ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. ºñ ¹ÙÀÌ·¯½º¼º Àü´Þ ½Ã¾à¿¡ ±âÃÊÇÑ ¿¬±¸´Â »ý¹°ÇÐ ¹× »ý¹° ÀÇÇÐ ºÐ¾ßÀÇ ±¤¹üÀ§ÇÑ ºÐ¾ß¿¡ °ÉÃÄ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î À¯ÀüÀÚ ±â´É ¿¬±¸¿¡¼­ ¿¬±¸ÀÚµéÀº ºñ ¹ÙÀÌ·¯½º¼º Àü´Þ ½Ã¾àÀ» »ç¿ëÇÏ¿© ƯÁ¤ À¯ÀüÀÚ ¹× Á¶Àý ÀÎÀÚ¸¦ ¼¼Æ÷¿¡ µµÀÔÇÕ´Ï´Ù. À̸¦ ÅëÇØ À¯ÀüÀÚ ¹ßÇö ÆÐÅÏ, Á¶Àý ¸ÞÄ¿´ÏÁò ¹× ´Ù¾çÇÑ ¼¼Æ÷ °úÁ¤¿¡¼­ À¯ÀüÀÚÀÇ ¿ªÇÒÀ» ¿¬±¸ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ »ý¸í°øÇÐ ¹× Á¦¾à »ê¾÷Àº ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº Áß±¹, ÀϺ», Çѱ¹ µîÀÇ ±¹°¡¿¡¼­ ƯÈ÷ µÎµå·¯Áý´Ï´Ù. ±× °á°ú, ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã¾àÀº Ç¥Àû ¼¼Æ÷¿¡ À¯Àü¹°ÁúÀ» Á¤È®ÇÏ°Ô Àü´ÞÇϰí À¯ÀüÀÚ Ä¡·á ¹× À¯ÀüÀÚ ÆíÁý ±â¼ú °³¹ßÀ» Áö¿øÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÀÌ Áö¿ªÀÇ »ý¹° ÀÇÇÐ ¿¬±¸ ¹× Ä¡·á ¹ßÀü¿¡¼­ ÀÌ·¯ÇÑ ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ÆÄŰ½ºÅºÀÇ Àα¸ ±¸¼ºÀº ´Ù¾çÇÏ°í ±ÙģȥÀÌ ¸¹À¸¸ç, ÀÌ´Â À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ºñ¹ÙÀÌ·¯½º¼º Àü»ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå - °æÀï ±¸µµ:

ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Thermo Fisher Scientific, Bio-Rad Laboratories, Innovio Pharmaceuticals, Maxite µîÀÌ ÀÖ½À´Ï´Ù. °¢ ȸ»ç´Â À¯ÀüÀÚ Á¶ÀÛ ¹× ¼¼Æ÷ °øÇÐ °ü·Ã ¿¬±¸¿Í Ä¡·á ÀÀ¿ëÀ» ÃËÁøÇϱâ À§ÇØ °íÀ¯ÇÑ ±â¼ú°ú Àü¹® Áö½ÄÀ» Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î MaxCyte´Â 1Â÷ ¼¼Æ÷, Áٱ⼼Æ÷, ¼¼Æ÷ÁÖ¿¡ ´ëÇÑ ÀϽÃÀû ¹× ¾ÈÁ¤µÈ ¼¼Æ÷ÁÖ ÁÖÀÔÀ» À§ÇÑ È®Àå °¡´ÉÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇϸç, MaxCyteÀÇ ½Ã½ºÅÛÀº ³ôÀº ÁÖÀÔ È¿À², È®À强, ¿¬±¸ ¹× ÀÓ»ó Àû¿ë °¡´É¼ºÀ¸·Î ÀÎÁ¤¹Þ°í ÀÖ½À´Ï´Ù. Æò°¡¹Þ°í ÀÖ½À´Ï´Ù.

BioRad Laboratories´Â Àü±â ÆÞ½º¸¦ Àû¿ëÇÏ¿© ¼¼Æ÷ ³»¿¡ °íÈ¿À²·Î ÇÙ»êÀ» µµÀÔÇÒ ¼ö ÀÖ´Â ÀÏ·ºÆ®·ÎÆ÷·¹À̼Ç(electroporation) ±â¹Ý ¼¼Æ÷ ÁÖÀÔ ½Ã½ºÅÛÀ» Àü¹®À¸·Î Çϰí ÀÖ½À´Ï´Ù. Bio-RadÀÇ ½Ã½ºÅÛÀº ¿¬±¸ ¹× ¹ÙÀÌ¿ÀÀǾàǰ ¿ëµµ¿¡¼­ À̽ÄÇϱ⠾î·Á¿î ¼¼Æ÷ ¹× 1Â÷ ¼¼Æ÷¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ »ê¾÷ ¿¬±¸

Á¦5Àå ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå : COVID-19 ¿µÇ⠺м®

Á¦6Àå ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå ±¸µµ

Á¦7Àå ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå - À¯Çüº°

Á¦8Àå ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå - ¿ëµµº°

Á¦9Àå ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ½ÃÀå - Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - ºñ¹ÙÀÌ·¯½º¼º Æ®·£½ºÆå¼Ç ½Ã¾à ¹× ½Ã½ºÅÛ ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Non-Viral Transfection Reagents and Systems Market size was valued at USD 786.23 Million in 2023, expanding at a CAGR of 8.2% from 2024 to 2032.

Non-viral transfection reagents are substances used in molecular biology and biotechnology to deliver genetic material (such as DNA or RNA) into cells without the use of viral vectors. They facilitate the introduction of nucleic acids into cells for various purposes, including gene expression studies, protein production, gene therapy, and genome editing.

Non-Viral Transfection Reagents and Systems Market- Market Dynamics

The need for Non-Viral Transfection Reagents in clinical settings is fueling their market growth.

Non-viral transfection is a compelling alternative to established methods, offering distinct advantages. These advantages include expedited timelines, enhanced biological efficiency, reduced cytotoxicity, and the ability to deliver a wider variety of nucleic acids. The pivotal role of non-viral transfection reagents in clinical applications is a key driver of their growth. These reagents facilitate the delivery of therapeutic nucleic acids, such as siRNA, miRNA, and DNA plasmids encoding therapeutic proteins or CRISPR/Cas9 genome editing tools. This capability paves the way for the development of innovative gene therapies for a broad spectrum of conditions, including genetic disorders, cancers, and infectious diseases.

The current landscape reflects a surge in activity by numerous companies actively developing advanced non-viral transfection reagents and systems. For example, recently, BioCentriq, a cell therapy expert, and Kytopen, an MIT startup, teamed up to develop innovative cell therapy manufacturing technology.

Non-Viral Transfection Reagents and Systems Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.2% over the forecast period (2024-2032)

Based on Type segmentation, non-viral transfection reagents were predicted to show maximum market share in the year 2023

Based on Application segmentation, Research Applications was the leading type in 2023

Based on End User segmentation, Pharmaceutical Companies were the leading type in 2023

Based on region, Asia-Pacific was the leading revenue generator in 2023

Non-Viral Transfection Reagents and Systems Market- Segmentation Analysis:

The Global Non-Viral Transfection Reagents and Systems Market is segmented based on Type, Application, End User, and Region.

The market is divided into three categories based on Type: Non-Viral Transfection Reagents, Electroporation-based Transfection Systems and Other Non-Viral Transfection Systems. Electroporation involves applying electrical pulses to cells in the presence of nucleic acids, creating temporary pores in the cell membrane through which genetic material can enter. Electroporation is known for its high transfection efficiency and is particularly effective for difficult-to-transfect cells and primary cells. It can be used for transient and stable transfection but requires specialized equipment and optimization for different cell types.

The market is divided into two categories based on Application: Clinical and Research. Research based on non-viral transfection reagents spans a wide spectrum of biological and biomedical fields. Such as in gene function studies, researchers employ non-viral transfection reagents to introduce specific genes or regulatory elements into cells. This allows them to study gene expression patterns, regulatory mechanisms, and the roles of genes in various cellular processes.

Non-Viral Transfection Reagents and Systems Market- Geographical Insights

The biotechnology and pharmaceutical industries in the Asia-Pacific region are expanding swiftly due to substantial investments in research and development. This growth is particularly pronounced in countries such as China, Japan, and South Korea. As a result, there is an increasing need for non-viral transfection reagents. These reagents are crucial for delivering genetic material precisely to target cells and supporting the development of gene therapy and gene editing technologies. Moreover, the rising prevalence of genetic disorders is contributing to the heightened demand for these reagents in the region's biomedical research and therapeutic advancements. For instance, the diverse makeup of Pakistan's population, characterized by significant levels of consanguinity, contributes to the higher prevalence of genetic disorders cases.

Non-Viral Transfection Reagents and Systems Market- Competitive Landscape:

Some of the key players in the Non-Viral Transfection Reagent and Systems Market are Thermo Fisher Scientific, Bio-Rad Laboratories, Inovio Pharmaceuticals, and MaxCyte. Each brings unique technologies and expertise to advance research and therapeutic applications involving genetic manipulation and cell engineering. For example, MaxCyte, is offering scalable solutions for transient and stable transfection of primary cells, stem cells, and cell lines. MaxCyte's systems are valued for their high transfection efficiency, scalability, and applicability in research and clinical settings.

Bio-Rad Laboratories specialises in electroporation-based transfection systems, which offer high efficiency for delivering nucleic acids into cells by applying electrical pulses. Bio-Rad's systems are widely used for difficult-to-transfect cells and primary cells in research and biopharmaceutical applications.

Recent Developments:

In Sept 2023, A new enterprise stemming from the University of Nottingham, dedicated to advancing a dry powder gene therapy formulation for bone graft augmentation, along with its partner, the University of Nottingham, has been granted £995,000 by Innovate UK, the UK's innovation agency.

In August 2023, Altogen Biosystems introduced a focused reagent designed to transport biomolecules to the lungs for treating patients with pulmonary diseases. The drug has safely and effectively transported small molecules, DNA, RNA, and proteins to the lungs.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Thermo Fisher Scientific (TFS)

Lonza Group

Imunon (Formerly known as Celsion)

Promega Corporation

Altogen Biosystems

Mirus Bio LLC

Genprex

Polyplus-Transfection SA

Bio-Rad Laboratories

MaxCyte

MilliporeSigma

Qiagen

Takara Bio

GLOBAL NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Non-Viral Transfection Reagents and Systems Market Overview

2. Executive Summary

3. Non-Viral Transfection Reagents and Systems Key Market Trends

4. Non-Viral Transfection Reagents and Systems Industry Study

5. Non-Viral Transfection Reagents and Systems Market: COVID-19 Impact Analysis

6. Non-Viral Transfection Reagents and Systems Market Landscape

7. Non-Viral Transfection Reagents and Systems Market - By Type

8. Non-Viral Transfection Reagents and Systems Market - By Application

9. Non-Viral Transfection Reagents and Systems Market - By End User

10. Non-Viral Transfection Reagents and Systems Market- By Geography

11. Key Vendor Analysis- Non-Viral Transfection Reagents and Systems Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â